ProJenX Announces Initial Closing of $15M Series A Financing and Appoints Rick Hartz to Board of Directors
Summary
ProJenX Announces Initial Closing of $15M Series A Financing and Appoints Rick Hartz to Board of DirectorsNEW YORK, Nov 2, 2023 ProJenX, Inc., a clinical-stage biotechnology company developing novel, brain-penetrant therapies targeting biologically-defined pathways for the treatment of amyotrophic lateral sclerosis (ALS) and other debilitating brain diseases, today announced the initial closing of a $15 million Series A financing. At Merck, he leads a global commercial team responsible for cardiovascular, respiratory, metabolic, infectious disease, hospital/specialty, immunology, and neuroscience. He earned a bachelors degree in economics from Dickinson College and an MBA from The Wharton School of the University of Pennsylvania.We are focused on accelerating the development of prosetin to meet the critical need for new treatments for people living with ALS, said Stan Abel, the companys president and CEO. We are encouraged by the therapeutic window emerging from our phase 1 trial and ongoing nonclinical studies and are looking forward to advancing prosetin to people living with ALS in early 2024. Prosetin is an investigational new drug and has not been approved by the FDA.ProJenX is a clinical-stage biotechnology company developing novel, brain-penetrant, targeted therapies to address untreatable brain diseases, with an initial focus on ALS.
Funding
Review available funding amount, funding date, investors, and linked company information related to ProJenX Announces Initial Closing of $15M Series A Financing and Appoints Rick Hartz to Board of Directors in the interactive ISVWorld profile.